Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +45

Zacks cuts Gilead to Hold as Gilead Sciences stock costs EUR 128.93

Analyst downgrade Guidance raised AI-generated analysis

πŸ“‰ Zacks Research downgraded Gilead Sciences from a strong buy to a hold rating on October 1, 2026.

πŸ’° Second-quarter 2026 revenue reached USD 7.80 billion, representing a 10% year-over-year increase.

πŸ“ˆ HIV sales grew 12% to USD 5.70 billion in the second quarter of 2026.

πŸ’Š Biktarvy sales increased 7% to USD 3.80 billion during the same reporting period.

πŸš€ Management raised full-year 2026 HIV sales growth guidance to 9-10% from 8%.

πŸ“Š The stock exceeded consensus revenue estimates of USD 7.37 billion in Q2 2026.

🏦 MarketBeat reports a Moderate Buy consensus with an average price target of USD 158.78.

πŸ“‰ HSBC raised its price target to USD 175.00 while maintaining a Buy rating on September 10, 2026.

πŸ’Ή Gilead Sciences stock traded at EUR 128.93 on October 6, 2026, up 0.11% from the prior close.

🏒 The company maintains a market capitalization of USD 179.3 billion as of October 5, 2026.

Bullish Signals
  • Gilead Sciences reported second-quarter 2026 revenue of USD 7.80 billion, which exceeded the consensus estimate of USD 7.37 billion.
  • HIV sales grew 12% year-over-year to reach USD 5.70 billion in the second quarter of 2026.
  • Biktarvy sales increased 7% to USD 3.80 billion, demonstrating strong performance for the company's key asset.
  • Management raised full-year 2026 HIV sales growth guidance to a range of 9-10%, up from the prior 8% expectation.
  • The broader analyst consensus remains positive with 23 Buy ratings versus only six Hold ratings.
Risk Factors
  • Zacks Research downgraded Gilead Sciences from a strong buy to a hold rating, citing expectations after a strong run.
  • The rating downgrade highlights investor scrutiny regarding whether new prevention products can extend growth beyond the established HIV treatment base.
Full Analysis
Gilead Sciences (GILD) received a rating downgrade from Zacks Research, which cut the stock from a strong buy to a hold on October 1, 2026. This analyst action contrasts with a broader positive consensus among other market participants, where 23 analysts maintain Buy ratings versus six Hold ratings, resulting in an average price target of USD 158.78. Financially, Gilead reported robust performance for the second quarter of 2026, posting revenue of USD 7.80 billion, a 10% year-over-year increase that exceeded consensus estimates of USD 7.37 billion. Excluding Veklury, product sales grew 10% to USD 7.60 billion, driven by strong growth in its core HIV franchise. Specifically, HIV sales surged 12% to USD 5.70 billion while Biktarvy sales increased 7% to USD 3.80 billion. Management subsequently raised full-year 2026 HIV sales growth guidance to a range of 9-10%, up from the previous 8% expectation, signaling confidence in the durability of its treatment base. The market reaction remained muted with shares trading slightly higher at EUR 128.93 on October 6, 2026, despite the Zacks downgrade. The company's market capitalization stands at USD 179.3 billion as investors weigh the strong current performance against expectations for new prevention products to extend growth beyond its established HIV portfolio.